Media headlines about Xencor (NASDAQ:XNCR) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Xencor earned a news impact score of 0.11 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.8383061564701 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
Several brokerages recently commented on XNCR. BidaskClub raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a research note on Friday. Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $37.00 price objective on shares of Xencor in a research note on Thursday, March 1st. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $35.00 price objective on shares of Xencor in a research note on Sunday, November 12th. Two equities research analysts have rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Xencor currently has a consensus rating of “Buy” and a consensus price target of $34.25.
Shares of Xencor (NASDAQ:XNCR) opened at $32.72 on Monday. Xencor has a 1 year low of $18.55 and a 1 year high of $33.00. The stock has a market cap of $1,540.00, a P/E ratio of -31.16 and a beta of 1.50.
In related news, major shareholder John S. Stafford III bought 9,215 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was acquired at an average cost of $20.76 per share, for a total transaction of $191,303.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder John S. Stafford III bought 6,215 shares of the company’s stock in a transaction on Tuesday, December 12th. The shares were bought at an average price of $20.72 per share, with a total value of $128,774.80. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 65,000 shares of company stock valued at $1,865,950. 4.03% of the stock is currently owned by company insiders.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.